Interactions : אינטראקציות

4.5   Interaction with other medicinal products and other forms of interaction

Somatostatin and its analogues competitively bind to somatostatin receptors and may interfere with the efficacy of LuNET-SRY. Therefore, administration of long-acting somatostatin analogues should be avoided within 30 days prior to the administration of this medicinal product. If necessary, patients may be treated with short-acting somatostatin analogues up to 24 hours preceding LuNET-SRY administration.
There is some evidence that corticosteroids can induce down-regulation of SST2 receptors. Therefore, as a matter of cautiousness, repeated administration of high-doses of glucocorticoids should be avoided during LuNET-SRY treatment. Patients with a history of chronic use of glucocorticoids should be carefully evaluated for sufficient somatostatin receptor expression. It is not known if there is of interaction between glucocorticoids used intermittently for the prevention of nausea and vomiting during LuNET-SRY administration. Therefore, glucocorticoids should be avoided as preventive anti-emetic treatment. In the case where the treatments previously provided for nausea and vomiting are insufficient, a single dose of corticosteroids can be used, as long as it is not given before initiating or within one hour after the end of LuNET-SRY infusion.
The absence of inhibition or significant induction of the human CYP450 enzymes, and the absence of specific interaction with P-glycoprotein (efflux transporter) or OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3 and BCRP transporters in pre-clinical studies, suggest that [177Lu]DOTA-TATE has a low probability of causing significant other drug-drug interactions.